12 February 2025 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the treatment of adults with advanced, BRCA mutation positive, HER2 negative advanced breast cancer after chemotherapy.

Olaparib is recommended as an option for the treatment of adults with locally advanced or metastatic, HER2 negative breast cancer with a germline BRCA1 or BRCA2 mutation who have had:

• An anthracycline and a taxane as neo-adjuvant or adjuvant treatment, or for metastatic disease, unless these are not suitable
• Endocrine therapy if they have hormone receptor positive breast cancer, unless this is not suitable

Olaparib is only recommended if AstraZeneca provides it according to the commercial arrangement.

Read NICE technology appraisal guidance